image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 29.58
-2.28 %
$ 954 M
Market Cap
12.64
P/E
1. INTRINSIC VALUE

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.[ Read More ]

The intrinsic value of one COLL stock under the base case scenario is HIDDEN Compared to the current market price of 29.6 USD, Collegium Pharmaceutical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart COLL

image
FINANCIALS
567 M REVENUE
22.17%
167 M OPERATING INCOME
259.66%
48.2 M NET INCOME
292.60%
275 M OPERATING CASH FLOW
121.16%
-70.8 M INVESTING CASH FLOW
87.66%
-140 M FINANCING CASH FLOW
-32.10%
159 M REVENUE
9.65%
34.8 M OPERATING INCOME
-26.61%
9.34 M NET INCOME
-52.39%
-9 M OPERATING CASH FLOW
-13.35%
-249 M INVESTING CASH FLOW
-2695.45%
149 M FINANCING CASH FLOW
230.49%
Balance Sheet Decomposition Collegium Pharmaceutical, Inc.
image
Current Assets 538 M
Cash & Short-Term Investments 311 M
Receivables 180 M
Other Current Assets 47.5 M
Non-Current Assets 606 M
Long-Term Investments 0
PP&E 22 M
Other Non-Current Assets 584 M
Current Liabilities 458 M
Accounts Payable 8.69 M
Short-Term Debt 185 M
Other Current Liabilities 264 M
Non-Current Liabilities 490 M
Long-Term Debt 496 M
Other Non-Current Liabilities -6.12 M
EFFICIENCY
Earnings Waterfall Collegium Pharmaceutical, Inc.
image
Revenue 567 M
Cost Of Revenue 241 M
Gross Profit 326 M
Operating Expenses 159 M
Operating Income 167 M
Other Expenses 119 M
Net Income 48.2 M
RATIOS
57.55% GROSS MARGIN
57.55%
29.46% OPERATING MARGIN
29.46%
8.50% NET MARGIN
8.50%
24.64% ROE
24.64%
4.21% ROA
4.21%
12.21% ROIC
12.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Collegium Pharmaceutical, Inc.
image
Net Income 48.2 M
Depreciation & Amortization 149 M
Capital Expenditures -461 K
Stock-Based Compensation 27.1 M
Change in Working Capital 21.7 M
Others 29.5 M
Free Cash Flow 274 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Collegium Pharmaceutical, Inc.
image
Wall Street analysts predict an average 1-year price target for COLL of $42.8 , with forecasts ranging from a low of $37 to a high of $50 .
COLL Lowest Price Target Wall Street Target
37 USD 25.08%
COLL Average Price Target Wall Street Target
42.8 USD 44.81%
COLL Highest Price Target Wall Street Target
50 USD 69.03%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Collegium Pharmaceutical, Inc.
image
Sold
0-3 MONTHS
1.13 M USD 2
3-6 MONTHS
5.15 M USD 3
6-9 MONTHS
1.34 M USD 3
9-12 MONTHS
3.63 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 13, 2024
Sell 351 K USD
Smith Thomas B
EVP and Chief Medical Officer
- 9593
36.6225 USD
2 months ago
Sep 05, 2024
Sell 643 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 16848
38.18 USD
2 months ago
Sep 05, 2024
Sell 93.9 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 2400
39.1421 USD
2 months ago
Sep 06, 2024
Sell 36.6 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 977
37.4556 USD
5 months ago
Jun 03, 2024
Sell 791 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 24300
32.5484 USD
5 months ago
Jun 03, 2024
Sell 23.3 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 700
33.22 USD
5 months ago
May 28, 2024
Sell 674 K USD
Tupper Colleen
EVP & Chief Financial Officer
- 19710
34.2145 USD
5 months ago
May 23, 2024
Sell 1.73 M USD
Dreyer Scott
EVP & Chief Commercial Officer
- 51209
33.824 USD
5 months ago
May 24, 2024
Sell 1.93 M USD
Dreyer Scott
EVP & Chief Commercial Officer
- 56807
33.9827 USD
6 months ago
May 14, 2024
Sell 936 K USD
BOHLIN GAREN G
Director
- 28985
32.3033 USD
8 months ago
Feb 29, 2024
Sell 36.6 K USD
Smith Thomas B
EVP and Chief Medical Officer
- 995
36.764 USD
8 months ago
Feb 26, 2024
Sell 340 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 9336
36.3754 USD
8 months ago
Feb 26, 2024
Sell 24.7 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 664
37.153 USD
10 months ago
Jan 16, 2024
Sell 761 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 23560
32.2801 USD
10 months ago
Dec 21, 2023
Sell 132 K USD
Ciaffoni Joseph
President and CEO
- 4357
30.3825 USD
10 months ago
Dec 19, 2023
Sell 436 K USD
Ciaffoni Joseph
President and CEO
- 14516
30.0318 USD
11 months ago
Dec 18, 2023
Sell 835 K USD
Ciaffoni Joseph
President and CEO
- 27798
30.0358 USD
10 months ago
Dec 20, 2023
Sell 804 K USD
Ciaffoni Joseph
President and CEO
- 26454
30.4003 USD
11 months ago
Nov 27, 2023
Sell 660 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 25600
25.7818 USD
1 year ago
Jun 26, 2023
Sell 360 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 16621
21.6544 USD
1 year ago
Jun 26, 2023
Sell 30.7 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 1363
22.5349 USD
1 year ago
Jun 01, 2023
Sell 691 K USD
Ciaffoni Joseph
President and CEO
- 31272
22.0887 USD
1 year ago
Jun 02, 2023
Sell 653 K USD
Ciaffoni Joseph
President and CEO
- 30272
21.5768 USD
1 year ago
Jun 02, 2023
Sell 22.3 K USD
Ciaffoni Joseph
President and CEO
- 1000
22.2511 USD
1 year ago
May 30, 2023
Sell 685 K USD
Ciaffoni Joseph
President and CEO
- 31271
21.9023 USD
1 year ago
May 31, 2023
Sell 684 K USD
Ciaffoni Joseph
President and CEO
- 31272
21.8661 USD
1 year ago
Mar 15, 2023
Sell 752 K USD
Tupper Colleen
EVP & Chief Financial Officer
- 31640
23.7726 USD
1 year ago
Mar 01, 2023
Sell 356 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 13324
26.7 USD
1 year ago
Feb 13, 2023
Sell 586 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 21811
26.88 USD
1 year ago
Feb 13, 2023
Sell 302 K USD
Ciaffoni Joseph
President and CEO
- 11250
26.88 USD
1 year ago
Jan 09, 2023
Sell 282 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 10424
27.08 USD
1 year ago
Jan 09, 2023
Sell 204 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 7341
27.83 USD
1 year ago
Jan 09, 2023
Sell 1.97 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 69
28.58 USD
1 year ago
Dec 27, 2022
Sell 92.3 K USD
Heffernan Michael Thomas
Director
- 3820
24.16 USD
1 year ago
Dec 22, 2022
Sell 2.53 K USD
Ciaffoni Joseph
President and CEO
- 110
23 USD
1 year ago
Dec 23, 2022
Sell 3.38 K USD
Ciaffoni Joseph
President and CEO
- 147
23 USD
1 year ago
Dec 27, 2022
Sell 42.7 K USD
Ciaffoni Joseph
President and CEO
- 1804
23.65 USD
1 year ago
Dec 27, 2022
Sell 9.68 K USD
Ciaffoni Joseph
President and CEO
- 400
24.19 USD
1 year ago
Dec 21, 2022
Sell 1.08 M USD
Heffernan Michael Thomas
Director
- 46600
23.11 USD
1 year ago
Dec 19, 2022
Sell 26.1 K USD
Ciaffoni Joseph
President and CEO
- 1134
23.01 USD
1 year ago
Dec 20, 2022
Sell 216 K USD
Ciaffoni Joseph
President and CEO
- 9375
23.07 USD
1 year ago
Dec 21, 2022
Sell 169 K USD
Ciaffoni Joseph
President and CEO
- 7333
23.11 USD
1 year ago
Dec 13, 2022
Sell 3.58 M USD
Heffernan Michael Thomas
Director
- 161687
22.16 USD
1 year ago
Dec 01, 2022
Sell 1.72 M USD
Ciaffoni Joseph
President and CEO
- 76653
22.47 USD
1 year ago
Dec 02, 2022
Sell 1.26 M USD
Ciaffoni Joseph
President and CEO
- 54400
23.07 USD
1 year ago
Nov 28, 2022
Sell 946 USD
Ciaffoni Joseph
President and CEO
- 43
22 USD
1 year ago
Nov 22, 2022
Sell 1.43 K USD
Ciaffoni Joseph
President and CEO
- 65
22 USD
2 years ago
Nov 18, 2022
Sell 43.8 K USD
Ciaffoni Joseph
President and CEO
- 1989
22.02 USD
2 years ago
Oct 04, 2022
Sell 75.5 K USD
Tupper Colleen
EVP & Chief Financial Officer
- 4350
17.35 USD
2 years ago
Sep 15, 2022
Sell 697 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 38589
18.07 USD
2 years ago
Aug 11, 2022
Sell 6 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 300
20.01 USD
2 years ago
Mar 01, 2022
Sell 1.2 M USD
Ciaffoni Joseph
President and CEO
- 65083
18.37 USD
2 years ago
Mar 01, 2022
Sell 210 K USD
Ciaffoni Joseph
President and CEO
- 11011
19.04 USD
2 years ago
Feb 18, 2022
Sell 228 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 10559
21.61 USD
2 years ago
Dec 15, 2021
Sell 104 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 5693
18.33 USD
3 years ago
Jun 01, 2021
Sell 123 K USD
Ciaffoni Joseph
President and CEO
- 5376
22.93 USD
3 years ago
Jun 01, 2021
Sell 253 K USD
Ciaffoni Joseph
President and CEO
- 10829
23.33 USD
3 years ago
Jun 02, 2021
Sell 134 K USD
Ciaffoni Joseph
President and CEO
- 5861
22.81 USD
3 years ago
May 10, 2021
Sell 159 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 7000
22.77 USD
3 years ago
Mar 15, 2021
Sell 1.19 M USD
Heffernan Michael Thomas
Director
- 47044
25.26 USD
3 years ago
Mar 15, 2021
Sell 78.4 K USD
Heffernan Michael Thomas
Director
- 3031
25.88 USD
3 years ago
Mar 01, 2021
Sell 1.24 M USD
Ciaffoni Joseph
President and CEO
- 54959
22.56 USD
3 years ago
Mar 01, 2021
Sell 229 K USD
Ciaffoni Joseph
President and CEO
- 9809
23.3 USD
6 years ago
Jan 19, 2018
Sell 33.3 K USD
Fleming Alison B
Chief Technical Officer
- 1449
23 USD
6 years ago
Jan 12, 2018
Sell 121 K USD
Fleming Alison B
Chief Technical Officer
- 5753
21 USD
6 years ago
May 10, 2018
Sell 37.8 K USD
Fleming Alison B
Chief Technical Officer
- 1400
27 USD
3 years ago
Mar 01, 2021
Sell 140 K USD
Fleming Alison B
Chief Technical Officer
- 6011
23.36 USD
3 years ago
Feb 11, 2021
Sell 52.3 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 2100
24.89 USD
3 years ago
Feb 11, 2021
Sell 147 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 5798
25.33 USD
3 years ago
Jan 20, 2021
Sell 149 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 6081
24.45 USD
3 years ago
Jan 20, 2021
Sell 149 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 6081
24.45 USD
3 years ago
Jan 15, 2021
Sell 30.3 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 1322
22.89 USD
6 years ago
Jan 19, 2018
Sell 76.7 K USD
Fleming Alison B
Chief Technology Officer
- 3336
23 USD
3 years ago
Jan 07, 2021
Sell 353 K USD
Fleming Alison B
Chief Technology Officer
- 16042
22 USD
3 years ago
Dec 03, 2020
Sell 115 K USD
Fleming Alison B
Chief Technology Officer
- 5967
19.24 USD
4 years ago
Oct 15, 2020
Sell 147 K USD
Kuhlmann Shirley R.
EVP and General Counsel
- 7060
20.82 USD
4 years ago
Aug 11, 2020
Sell 250 K USD
Heffernan Michael Thomas
Director
- 13071
19.13 USD
4 years ago
Jul 13, 2020
Sell 24.3 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 1429
17.01 USD
4 years ago
Jun 01, 2020
Sell 1.52 M USD
Ciaffoni Joseph
President and CEO
- 70576
21.53 USD
4 years ago
Jun 01, 2020
Sell 2.21 K USD
Ciaffoni Joseph
President and CEO
- 100
22.08 USD
4 years ago
Jun 02, 2020
Sell 118 K USD
Ciaffoni Joseph
President and CEO
- 5761
20.47 USD
4 years ago
Jun 02, 2020
Sell 2.13 K USD
Ciaffoni Joseph
President and CEO
- 100
21.3 USD
4 years ago
May 18, 2020
Sell 192 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 8000
24 USD
4 years ago
May 13, 2020
Sell 28.9 K USD
Heffernan Michael Thomas
Director
- 1380
20.92 USD
4 years ago
May 13, 2020
Sell 254 K USD
Heffernan Michael Thomas
Director
- 11969
21.21 USD
4 years ago
May 13, 2020
Sell 134 K USD
Heffernan Michael Thomas
Director
- 5905
22.64 USD
4 years ago
May 13, 2020
Sell 111 K USD
Fleming Alison B
Chief Technology Officer
- 5261
21.12 USD
4 years ago
May 13, 2020
Sell 62 K USD
Fleming Alison B
Chief Technology Officer
- 2728
22.74 USD
4 years ago
May 13, 2020
Sell 100 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 4434
22.61 USD
4 years ago
Jan 21, 2020
Sell 5.73 M USD
Heffernan Michael Thomas
Director
- 262587
21.84 USD
4 years ago
Jan 21, 2020
Sell 742 K USD
Heffernan Michael Thomas
Director
- 32700
22.69 USD
4 years ago
Jan 14, 2020
Sell 31.5 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 1321
23.87 USD
5 years ago
Nov 08, 2019
Sell 483 K USD
Hirsch David
Director
- 25000
19.33 USD
5 years ago
Nov 08, 2019
Sell 486 K USD
Fleming Alison B
Chief Technology Officer
- 25000
19.44 USD
5 years ago
Nov 07, 2019
Sell 618 K USD
Ciaffoni Joseph
President and CEO
- 33595
18.41 USD
5 years ago
Nov 07, 2019
Sell 598 K USD
Ciaffoni Joseph
President and CEO
- 31226
19.16 USD
5 years ago
Aug 29, 2019
Sell 258 K USD
Hirsch David
Director
- 22106
11.65 USD
5 years ago
Jul 15, 2019
Sell 282 K USD
Heffernan Michael Thomas
Director
- 25000
11.26 USD
5 years ago
Jul 11, 2019
Sell 35.2 K USD
Dreyer Scott
EVP & Chief Commercial Officer
- 2857
12.31 USD
5 years ago
Jun 17, 2019
Sell 260 K USD
Heffernan Michael Thomas
Director
- 22979
11.31 USD
5 years ago
Jun 17, 2019
Sell 24.4 K USD
Heffernan Michael Thomas
Director
- 2021
12.05 USD
5 years ago
May 31, 2019
Sell 67.4 K USD
Ciaffoni Joseph
President and CEO
- 5851
11.52 USD
5 years ago
Jun 03, 2019
Sell 86.2 K USD
Ciaffoni Joseph
President and CEO
- 7436
11.59 USD
5 years ago
May 15, 2019
Sell 235 K USD
Heffernan Michael Thomas
Director
- 18483
12.74 USD
5 years ago
May 15, 2019
Sell 85.6 K USD
Heffernan Michael Thomas
Director
- 6517
13.13 USD
5 years ago
Apr 15, 2019
Sell 301 K USD
Heffernan Michael Thomas
Director
- 20192
14.91 USD
5 years ago
Apr 15, 2019
Sell 76.3 K USD
Heffernan Michael Thomas
Director
- 4808
15.87 USD
5 years ago
Mar 15, 2019
Sell 429 K USD
Heffernan Michael Thomas
Director
- 25000
17.17 USD
5 years ago
Feb 15, 2019
Sell 264 K USD
Heffernan Michael Thomas
Director
- 17932
14.71 USD
5 years ago
Feb 15, 2019
Sell 106 K USD
Heffernan Michael Thomas
Director
- 7068
15.06 USD
5 years ago
Jan 15, 2019
Sell 389 K USD
Heffernan Michael Thomas
Director
- 25000
15.56 USD
5 years ago
Dec 17, 2018
Sell 393 K USD
Heffernan Michael Thomas
Director
- 21687
18.12 USD
5 years ago
Dec 17, 2018
Sell 61.5 K USD
Heffernan Michael Thomas
Director
- 3313
18.57 USD
6 years ago
Nov 15, 2018
Sell 354 K USD
Heffernan Michael Thomas
Director
- 21400
16.53 USD
6 years ago
Nov 15, 2018
Sell 61.4 K USD
Heffernan Michael Thomas
Director
- 3600
17.05 USD
6 years ago
Oct 15, 2018
Sell 413 K USD
Heffernan Michael Thomas
Director
- 25000
16.53 USD
6 years ago
Jun 21, 2018
Sell 140 K USD
Brannelly Paul
Executive Vice President & CFO
- 5100
27.5 USD
6 years ago
Jun 21, 2018
Sell 139 K USD
Brannelly Paul
Executive Vice President & CFO
- 4900
28.35 USD
6 years ago
Jun 12, 2018
Sell 111 K USD
Fleming Alison B
Chief Technology Officer
- 4096
27 USD
6 years ago
Jun 11, 2018
Sell 2.45 M USD
Heffernan Michael Thomas
Chairman, President and CEO
- 96943
25.28 USD
6 years ago
Jun 12, 2018
Sell 1.34 M USD
Heffernan Michael Thomas
Chairman, President and CEO
- 53057
25.26 USD
6 years ago
May 31, 2018
Sell 1.33 M USD
Ciaffoni Joseph
Chief Operating Officer
- 59204
22.54 USD
6 years ago
May 31, 2018
Sell 131 K USD
Ciaffoni Joseph
Chief Operating Officer
- 5617
23.35 USD
6 years ago
Jun 01, 2018
Sell 334 K USD
Ciaffoni Joseph
Chief Operating Officer
- 14862
22.48 USD
6 years ago
May 10, 2018
Sell 146 K USD
Heffernan Michael Thomas
Chairman, President and CEO
- 5600
26 USD
6 years ago
May 10, 2018
Sell 40.5 K USD
Heffernan Michael Thomas
Chairman, President and CEO
- 1500
27 USD
6 years ago
Apr 19, 2018
Sell 1.15 M USD
Heffernan Michael Thomas
Chairman, President and CEO
- 44300
26 USD
6 years ago
Apr 19, 2018
Sell 2.6 K USD
Heffernan Michael Thomas
Chairman, President and CEO
- 100
26.01 USD
6 years ago
Jan 22, 2018
Sell 89.8 K USD
Heffernan Michael Thomas
Chairman, President and CEO
- 3592
25 USD
6 years ago
Jan 23, 2018
Sell 410 K USD
Heffernan Michael Thomas
Chairman, President and CEO
- 16408
25.01 USD
6 years ago
Jan 19, 2018
Sell 450 K USD
Heffernan Michael Thomas
Chairman, President and CEO
- 20000
22.5 USD
6 years ago
Jan 10, 2018
Sell 132 K USD
Fleming Alison B
Chief Technology Officer
- 6928
19.07 USD
6 years ago
Dec 08, 2017
Sell 17 M USD
Hirsch David
director, 10 percent owner:
- 980350
17.34 USD
6 years ago
Dec 08, 2017
Sell 341 K USD
Hirsch David
director, 10 percent owner:
- 19650
17.34 USD
6 years ago
Dec 08, 2017
Sell 17 M USD
Longitude Capital Partners, LLC
10 percent owner
- 980350
17.34 USD
6 years ago
Dec 08, 2017
Sell 341 K USD
Longitude Capital Partners, LLC
10 percent owner
- 19650
17.34 USD
7 years ago
Nov 17, 2017
Sell 21.1 K USD
Fleming Alison B
Chief Technology Officer
- 1239
17 USD
7 years ago
Nov 17, 2017
Sell 14.3 K USD
Fleming Alison B
Chief Technology Officer
- 840
17 USD
6 years ago
Nov 21, 2017
Sell 10.9 K USD
Fleming Alison B
Chief Technology Officer
- 572
19 USD
7 years ago
Nov 15, 2017
Sell 776 K USD
Heffernan Michael Thomas
Chairman, President and CEO
- 50000
15.53 USD
7 years ago
May 12, 2017
Bought 91.8 K USD
Brannelly Paul
Executive Vice President & CFO
+ 10000
9.18 USD
7. News
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD) MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children. globenewswire.com - 2 days ago
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 3 days ago
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock? Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately. zacks.com - 1 week ago
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 1 week ago
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 week ago
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago. zacks.com - 1 week ago
Collegium Reports Record Third Quarter 2024 Financial Results – Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca ® Revenue of $53.2 Million and Record Xtampza ® ER Revenue of $49.5 Million – globenewswire.com - 1 week ago
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2 weeks ago
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Breakouts Boost These Three Stocks To All-Time Highs Three stocks, Blue Owl Capital, Collegium Pharmaceuticals and Armstrong World Industries are at their all time high as they break out from proper bases. investors.com - 1 month ago
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
8. Profile Summary

Collegium Pharmaceutical, Inc. COLL

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 954 M
Dividend Yield 0.00%
Description Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Contact 100 Technology Center Drive, Stoughton, MA, 02072 https://www.collegiumpharma.com
IPO Date May 7, 2015
Employees 197
Officers Mr. Scott Sudduth Head of Technical Operations Ms. Colleen Tupper Executive Vice President & Chief Financial Officer Dr. Thomas B. Smith FAAFP, M.D. Executive Vice President & Chief Medical Officer Dr. Christopher Shayne James M.D. Vice President of Investor Relations Mr. Scott Dreyer Executive Vice President & Chief Commercial Officer Mr. Bart J. Dunn Executive Vice President of Strategy & Corporate Development